Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | KDM6B | O15054 | 1/20 | 0.63 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.63 |
| ▸ | PLK1 | P53350 | 4/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466141 | 0.95 | PLK1 (0.63) | HPGDALDH1A1HSD17B10CYP2C9KDM6B | |
| SCHEMBL11430175 | 0.93 | PLK1 (0.66) | HPGDALDH1A1HSD17B10CYP2C9KDM6B | |
| SCHEMBL11432358 | 0.93 | PLK1 (0.66) | HPGDALDH1A1HSD17B10CYP2C9KDM6B | |
| SCHEMBL11437269 | 0.93 | PLK1 (0.66) | HPGDALDH1A1HSD17B10CYP2C9KDM6B | |
| SCHEMBL5694119 | 0.93 | PLK1 (0.66) | HPGDALDH1A1HSD17B10CYP2C9KDM6B | |
| SCHEMBL5272720 | 0.93 | PLK1 (0.66) | HPGDALDH1A1HSD17B10CYP2C9KDM6B | |
| SCHEMBL3475665 | 0.93 | PLK1 (0.66) | HPGDALDH1A1HSD17B10CYP2C9KDM6B | |
| SCHEMBL11443814 | 0.93 | PLK1 (0.66) | HPGDALDH1A1HSD17B10CYP2C9KDM6B | |
| SCHEMBL10475728 | 0.93 | PLK1 (0.66) | HPGDALDH1A1HSD17B10CYP2C9KDM6B | |
| SCHEMBL11483067 | 0.93 | PLK1 (0.66) | HPGDALDH1A1HSD17B10CYP2C9KDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4436552-B1 | GASTRO-RETENTIVE ORAL DOSAGE UNIT CONTAINING A LOCAL ANAESTHETIC | OREXA B V (NL) | 2026-02-04 | — | — | EP | claimed |
| WO-2024182515-A1 | AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2024-09-06 | — | — | WO | claimed |
| US-20240292836-A1 | AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2024-09-05 | — | — | US | claimed |
| EP-2890494-B1 | COMPOSITE CATALYST, PREPARATION PROCESS THEREOF, AND PROCESS FOR CATALYZING THE TRIMERIZATION OF BUTADIENE USING THE COMPOSITE CATALYST | WANHUA CHEMICAL GROUP CO LTD (CN) | 2021-11-24 | — | — | EP | claimed |
| US-9365596-B2 | Method for preparing quaternary phosphonium salts | MICROVAST POWER SYSTEMS CO., LTD. (CN) | 2016-06-14 | — | — | US | claimed |
| US-20150166587-A1 | METHOD FOR PREPARING QUATERNARY PHOSPHONIUM SALTS | MICROVAST POWER SYSTEMS CO., LTD. (CN) | 2015-06-18 | — | — | US | claimed |
| EP-2066301-B1 | INJECTABLE PHARMACEUTICAL NIMESULIDE SOLUTIONS | PHARMATEX ITALIA SRL (IT) | 2010-08-25 | — | — | EP | claimed |
| EP-2066301-A1 | INJECTABLE PHARMACEUTICAL NIMESULIDE SOLUTIONS | Pharmatex Italia Srl (IT) | 2009-06-10 | — | — | EP | claimed |
| WO-2008034819-A1 | INJECTABLE PHARMACEUTICAL NIMESULIDE SOLUTIONS | PHARMATEX ITALIA SRL (IT) | 2008-03-27 | — | — | WO | claimed |
| EP-1902705-A1 | Injectable pharmaceutical nimesulide solutions | Pharmatex Italia Srl (IT) | 2008-03-26 | — | — | EP | claimed |
| EP-0770387-B1 | Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic | BRAUN MELSUNGEN AG (DE) | 1999-08-11 | — | — | EP | claimed |
| EP-0770387-A1 | Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic | B. BRAUN MELSUNGEN AG (DE) | 1997-05-02 | — | — | EP | claimed |
| EP-0512547-B1 | Pain controlling composition and method of preparation | SHULMAN MORTON (US) | 1997-04-23 | — | — | EP | claimed |
| EP-0553351-B1 | CRYSTALLINE MODIFICATION OF HYDROCHLORIDE OF 2-DIMETHYLAMINOETHYL ETHER OF n-BUTYLAMINO BENZOIC ACID, METHOD OF OBTAINING IT AND PHARMACEUTICAL PREPARATION FOR ANESTHESIA OF THE EYE BASED THEREUPON | LEONIDOV NIKOLAI B (RU) | 1995-12-27 | — | — | EP | claimed |
| US-5298257-A | Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method | ELAN TRANSDERMAL LIMITED (IE) | 1994-03-29 | — | — | US | claimed |
| EP-0553351-A1 | CRYSTALLINE MODIFICATION OF HYDROCHLORIDE OF 2-DIMETHYLAMINOETHYL ETHER OF n-BUTYLAMINO BENZOIC ACID, METHOD OF OBTAINING IT AND PHARMACEUTICAL PREPARATION FOR ANESTHESIA OF THE EYE BASED THEREUPON | LEONIDOV, Nikolai Borisovich (RU) | 1993-08-04 | — | — | EP | claimed |
| EP-0197308-B1 | COMPOSITION AND METHOD FOR PRODUCING PROLONGED PAIN RELIEF | Shulman, Morton (US) | 1991-04-10 | — | — | EP | claimed |
| US-4946853-A | Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method | ELAN TRANSDERMAL LIMITED (IE) | 1990-08-07 | — | — | US | claimed |
| EP-0197308-A2 | Composition and method for producing prolonged pain relief | Shulman, Morton (US) | 1986-10-15 | — | — | EP | claimed |
| US-4041174-A | INJECTING AN ESTER LOCAL ANESTHETIC | ROM-AMER PHARMACEUTICALS, LTD. (US) | 1977-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240292836-A1 | AGENTS FOR REPELLING, KNOCKING DOWN, AND/OR KILLING BLOOD-SUCKING ARTHROPODS AND USES THEREOF | L3MBTL4, L3MBTL3, L3MBTL1 | HPGD 4461/4885ALDH1A1 3333/4885HSD17B10 2791/4885 |
| US-20150166587-A1 | METHOD FOR PREPARING QUATERNARY PHOSPHONIUM SALTS | PHPT1, PHOSPHO1, PTEN | HPGD 2655/4885ALDH1A1 4827/4885HSD17B10 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.